Engineered Nanoparticulate Vaccines to Combat Recurring and Pandemic Influenza Threats
Chunhong Dong
◽
Bao-Zhong Wang
2006 ◽
Vol 39
(19)
◽
pp. 47
A Ahmad
◽
R Krumkamp
◽
S Mounier-Jack
◽
R Reintjes
◽
R Coker
2006 ◽
Vol 17
(9)
◽
pp. 36
◽
2012 ◽
Vol 130
(3)
◽
pp. X2-X2
2017 ◽
Vol 82
(2)
◽
pp. 47-51
O.V. Konakova
◽
◽
O.V. Ysachova
◽
E.A. Silina
◽
T.M. Pakholchuk
◽
...
Human medicines European public assessment report (EPAR): Foclivia, pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted), Influenza, Human,Immunization,Disease Outbreaks, Date of authorisation: 18/10/2009, Revision: 8, Status: Authorised
Human medicines European public assessment report (EPAR): Adjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals), pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted), Influenza, Human,Immunization,Disease Outbreaks, Date of authorisation: 10/10/2009, Revision: 9, Status: Authorised
Laxmi Baxi
◽
Tessie Tharakan